MedTrace Logo

A Single Dose Study Of PF-06678552 In Healthy Subjects

NCT01992614 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-03-28

No results posted yet for this study

Summary

PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06678552 in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

PF-06678552 or Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.

DRUG

PF-06678552 or Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.

DRUG

PF-06678552 or Placebo

PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992614 on ClinicalTrials.gov